
The FDA designates litifilimab as a breakthrough therapy for cutaneous lupus erythematosus, highlighting its potential to transform treatment options.

The FDA designates litifilimab as a breakthrough therapy for cutaneous lupus erythematosus, highlighting its potential to transform treatment options.